{"id":729861,"date":"2023-02-08T16:13:21","date_gmt":"2023-02-08T21:13:21","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/pulmonx-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-22-2023\/"},"modified":"2023-02-08T16:13:21","modified_gmt":"2023-02-08T21:13:21","slug":"pulmonx-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-22-2023","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/pulmonx-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-22-2023\/","title":{"rendered":"Pulmonx to Report Fourth Quarter and Full Year 2022 Financial Results on February 22, 2023"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">REDWOOD CITY, Calif., Feb.  08, 2023  (GLOBE NEWSWIRE) &#8212; Pulmonx Corporation (Nasdaq: LUNG) (\u201cPulmonx\u201d), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the fourth quarter and full year of 2022 after the close of trading on Wednesday, February 22, 2023. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT\u00a0\/\u00a04:30 p.m. ET.<\/p>\n<p align=\"justify\">A live and archived webcast of the event will be available on the \u201cInvestors\u201d section of the Pulmonx website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zd2icgsz-O4Cm1c9wMg4w46jB2pHm_CvEVTqmI9WLCQFm85fgH62wkSLi21NgQWI8v4cWgdKPhwz0ZHamW5Qp0dR2toAZfR3fKHFjGFOJUJia_bv9uhK2bi1DO5m830d\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/investors.pulmonx.com\/<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About Pulmonx Corporation<\/strong><br \/>\n        <br \/>Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for severe lung disease. Pulmonx\u2019s Zephyr\u00ae Endobronchial Valve, Chartis\u00ae Pulmonary Assessment System and StratX\u00ae Lung Analysis Platform are designed to assess and treat patients with severe emphysema\/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a \u201cbreakthrough device.\u201d The Zephyr Valve is commercially available in more than 25 countries, with over 100,000 valves used to treat more than 25,000 patients. For more information on the Zephyr Valves, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zd2icgsz-O4Cm1c9wMg4w6P1c5r_cqPDLAF_uFitjui4nfjjcpnigCr3cPo42bP3XkFvcPSRq6TqvNNQa34ISD2QKvXkDSQS4kBeQ4nmKDK4gQ5OZ4FdSenIW4IztCTh\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/uspatients.pulmonx.com\/<\/a>. For more information on the company, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=KqcRRoQJT--mDS_TgJkQYx-rEKtOI5J1bu0c9jVl7oejmJgcY7p_WcoKRtROji_0XPEntBkBs1OguWbec7ScpQ==\" rel=\"nofollow noopener\" target=\"_blank\">www.Pulmonx.com<\/a>.<\/p>\n<p align=\"justify\">Pulmonx\u00ae, Chartis\u00ae, StratX\u00ae, and Zephyr\u00ae are registered trademarks of Pulmonx Corporation.<\/p>\n<p align=\"justify\">\n        <strong>Contact<\/strong><br \/>\n        <br \/>Brian Johnston<br \/>Gilmartin Group<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=opd2KUgxiMUL_YrQwIAw9UAXOsGh6QpqV7fT-d5hYnYn3D2Pr_4vw5sMZEx4nGFjxfne-KHhkCBGLxC9aA3Bz1Zo7s7lDcPcaLn6H6fkD9Q=\" rel=\"nofollow noopener\" target=\"_blank\">investors@pulmonx.com<\/a><\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0NDU4MyM1Mzk2NDgzIzIxOTQ1ODk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MGFkNzM2OWUtMzA1OC00OWY5LThjMmMtNGVhZDMyNDNjMjQ1LTEyMDYxNDI=\/tiny\/Pulmonx-Corporation.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>REDWOOD CITY, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) &#8212; Pulmonx Corporation (Nasdaq: LUNG) (\u201cPulmonx\u201d), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the fourth quarter and full year of 2022 after the close of trading on Wednesday, February 22, 2023. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT\u00a0\/\u00a04:30 p.m. ET. A live and archived webcast of the event will be available on the \u201cInvestors\u201d section of the Pulmonx website at https:\/\/investors.pulmonx.com\/. About Pulmonx Corporation Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for severe lung disease. Pulmonx\u2019s Zephyr\u00ae Endobronchial Valve, Chartis\u00ae Pulmonary Assessment System and StratX\u00ae Lung &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pulmonx-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-22-2023\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Pulmonx to Report Fourth Quarter and Full Year 2022 Financial Results on February 22, 2023&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-729861","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Pulmonx to Report Fourth Quarter and Full Year 2022 Financial Results on February 22, 2023 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pulmonx-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-22-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pulmonx to Report Fourth Quarter and Full Year 2022 Financial Results on February 22, 2023 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"REDWOOD CITY, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) &#8212; Pulmonx Corporation (Nasdaq: LUNG) (\u201cPulmonx\u201d), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the fourth quarter and full year of 2022 after the close of trading on Wednesday, February 22, 2023. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT\u00a0\/\u00a04:30 p.m. ET. A live and archived webcast of the event will be available on the \u201cInvestors\u201d section of the Pulmonx website at https:\/\/investors.pulmonx.com\/. About Pulmonx Corporation Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for severe lung disease. Pulmonx\u2019s Zephyr\u00ae Endobronchial Valve, Chartis\u00ae Pulmonary Assessment System and StratX\u00ae Lung &hellip; Continue reading &quot;Pulmonx to Report Fourth Quarter and Full Year 2022 Financial Results on February 22, 2023&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/pulmonx-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-22-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-08T21:13:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0NDU4MyM1Mzk2NDgzIzIxOTQ1ODk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulmonx-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-22-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulmonx-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-22-2023\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Pulmonx to Report Fourth Quarter and Full Year 2022 Financial Results on February 22, 2023\",\"datePublished\":\"2023-02-08T21:13:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulmonx-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-22-2023\\\/\"},\"wordCount\":231,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulmonx-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-22-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0NDU4MyM1Mzk2NDgzIzIxOTQ1ODk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulmonx-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-22-2023\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulmonx-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-22-2023\\\/\",\"name\":\"Pulmonx to Report Fourth Quarter and Full Year 2022 Financial Results on February 22, 2023 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulmonx-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-22-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulmonx-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-22-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0NDU4MyM1Mzk2NDgzIzIxOTQ1ODk=\",\"datePublished\":\"2023-02-08T21:13:21+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulmonx-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-22-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulmonx-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-22-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulmonx-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-22-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0NDU4MyM1Mzk2NDgzIzIxOTQ1ODk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0NDU4MyM1Mzk2NDgzIzIxOTQ1ODk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pulmonx-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-22-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pulmonx to Report Fourth Quarter and Full Year 2022 Financial Results on February 22, 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pulmonx to Report Fourth Quarter and Full Year 2022 Financial Results on February 22, 2023 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/pulmonx-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-22-2023\/","og_locale":"en_US","og_type":"article","og_title":"Pulmonx to Report Fourth Quarter and Full Year 2022 Financial Results on February 22, 2023 - Market Newsdesk","og_description":"REDWOOD CITY, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) &#8212; Pulmonx Corporation (Nasdaq: LUNG) (\u201cPulmonx\u201d), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the fourth quarter and full year of 2022 after the close of trading on Wednesday, February 22, 2023. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT\u00a0\/\u00a04:30 p.m. ET. A live and archived webcast of the event will be available on the \u201cInvestors\u201d section of the Pulmonx website at https:\/\/investors.pulmonx.com\/. About Pulmonx Corporation Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for severe lung disease. Pulmonx\u2019s Zephyr\u00ae Endobronchial Valve, Chartis\u00ae Pulmonary Assessment System and StratX\u00ae Lung &hellip; Continue reading \"Pulmonx to Report Fourth Quarter and Full Year 2022 Financial Results on February 22, 2023\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/pulmonx-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-22-2023\/","og_site_name":"Market Newsdesk","article_published_time":"2023-02-08T21:13:21+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0NDU4MyM1Mzk2NDgzIzIxOTQ1ODk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pulmonx-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-22-2023\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pulmonx-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-22-2023\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Pulmonx to Report Fourth Quarter and Full Year 2022 Financial Results on February 22, 2023","datePublished":"2023-02-08T21:13:21+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pulmonx-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-22-2023\/"},"wordCount":231,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pulmonx-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-22-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0NDU4MyM1Mzk2NDgzIzIxOTQ1ODk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pulmonx-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-22-2023\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/pulmonx-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-22-2023\/","name":"Pulmonx to Report Fourth Quarter and Full Year 2022 Financial Results on February 22, 2023 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pulmonx-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-22-2023\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pulmonx-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-22-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0NDU4MyM1Mzk2NDgzIzIxOTQ1ODk=","datePublished":"2023-02-08T21:13:21+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pulmonx-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-22-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/pulmonx-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-22-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pulmonx-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-22-2023\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0NDU4MyM1Mzk2NDgzIzIxOTQ1ODk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0NDU4MyM1Mzk2NDgzIzIxOTQ1ODk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pulmonx-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-22-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Pulmonx to Report Fourth Quarter and Full Year 2022 Financial Results on February 22, 2023"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/729861","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=729861"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/729861\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=729861"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=729861"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=729861"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}